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Clinical Infertility in Women
by Griff T. Ross*
Fertility results from coordinate functioning of components of the hypothalamic-pituitary-ovarian-
genital axis. In normal women, ovarian sex steroid hormones act as the mediators ofthese interactions.
Infertility is a clinical manifestation of the failure of one or more of the components to function
appropriately. Determining the locus ofdysfunction provides the basis for rational treatment. For these
purposes, both direct measurement ofserum hormone levels and assessments oftarget organ function are
utilized.
Introduction
The hormonal and gametogenic functions of the
ovary, described earlier, are integrated into a sys-
tem to assure fertility. When the system functions
normally, oocytes escape from the ovary by ovula-
tion and enterthe fallopian tube where they undergo
transformation into fertilizable ova. Then the pro-
nuclei of sperm and ovum fuse (fertilization), and
cell divisions produce a blastula. The blastula is
transported into the uterus, where it implants if the
endometrium is properly prepared and pregnancy
ensues.
If the sequence of events described is to occur,
function of the ovaries, the hypothalamic-pituitary
unit, and the genital tract must be coordinated.
Failure of appropriate functioning of these compo-
nents results in infertility. In discussing clinical
problems of infertility in women, we will examine
first the coordination of these component interac-
tions in normal women and then consider methods
for evaluating the locus of disordered function in
women who have been unable to conceive.
The Normal Hypothalamic-
Pituitary-Ovarian-Genital Axis
The hypothalamus secretes hypophysiotropic
hormones which stimulate the pituitary to produce
the gonadotrophins, follicle-stimulating hormone
(FSH) and luteinizing hormone (LH) which can be
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measured in specimens of peripheral blood.
Gonadotrophins are delivered to the ovaries where
these hormones stimulate both folliculargrowth and
steroid hormone synthesis and secretion. Although
several sex steroid hormones are secreted, the im-
portant ones for our discussion consist in estradiol-
17,8 (E2), 17-a hydroxyprogesterone (17 OH-P), and
progesterone (P). Concentrations of E2, 17 OH-P,
and P in peripheral blood are resultants ofsecretion
by the ovaries and ofmetabolic processes, including
metabolic clearance, that metabolize and remove
these hormones from the blood (1). Comparisons of
concentrations of these steroids in venous effluent
from the two ovaries reveal that levels in peripheral
blood in the second half of the preovulatory phase
of the cycle reflect the secretory activity of the
ovary containing the follicle which will give rise to
the oocyte that is ovulated during that cycle (2, 3).
Similarly, the concentrations of E2, 17 OH-P, and P
in venous effluent from the ovary containing the
corpus luteum are much higher than those in the
venous effluent from the contralateral ovary (2, 3).
Thus, concentrations of E2, 17 OH-P, and P in
peripheral blood reflect the growth and maturation
of the dominant follicle prior to and of the func-
tioning corpus luteum after ovulation. Since the
corpus luteum is derived from the follicle which
ovulated, it is not surprising that there is evidence
to support the contention that the functional capac-
ity of the corpus luteum is predetermined by the
hormonal milieu in which the preovulatory follicle
develops (4, 5).
There is direct evidence in animal model systems
(6, 7) and indirect evidence in the human (8) that
within the ovary, the sex steroid hormones mod-
ulate growth and atresia of the ovarian follicles. In
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within the ovary, the steroid hormones "feed back"
on the hypothalamic-pituitary unit to modulate
gonadotrophin synthesis and secretion (9). Thus
levels of E2, 17 OH-P, and P in peripheral blood are
representative of the concentrations which perfuse
the hypothalamic-pituitary unit to modulate
gonadotrophin secretion and coordinate interactions
of the two components during ovulatory cycles.
Steroid hormones also coordinate the functioning
of the ovary and the hypothalamic-pituitary unit
with that of the genital tract (1). These hormones
stimulate proliferation ofgenital tract epithelia, reg-
ulate the quality and quantity of secretory products
of these tissues, particularly the endometrium and
the endocervical glands, and regulate the motility of
the fallopian tubes and uterine contractions.
These component interactions are summarized
diagramatically in Figure 1. From the figure, it is
apparent that one could assess function ofthe com-
ponents by measuring concentrations of sex steroid
hormones and gonadotrophins in appropriately
collected specimens of peripheral blood and deter-
mine the appropriateness of genital tract responses
by monitoring changes in the morphology ofthe en-
dometrium, in the quality and quantity of endocer-
vical mucus, and in the character of vaginal epithe-
lial cells. Since measurement of hormone concen-
trations in peripheral blood is expensive and time
consuming, daily sampling is impractical. However,
as we shall see, a limited number of samples, col-
lected at appropriate times, provide critical diag-
nostic information.
Clinical Evaluation of
Women with Infertility
In determining the pathophysiologic basis of in-
fertility, it is important at the outset to establish that
the husband produces adequate numbers of normal
sperm. Failure to demonstrate that the quantity of
semen is adequate and that the sperm are normally
motile can result in unnecessary and expensive
testing of perfectly normal women.
For purposes of this presentation, women who
come to the physician for evaluation of the
pathophysiologic basis of their failure to conceive
may be grouped into three categories. The first con-
sists of women who have undergone puberty but
failed to conceive despite two years ofunprotected
intercourse. The second consists of women who
have completed puberty normally but have sub-
sequently ceased to menstruate, that is, women
with secondary amenorrhea. The third group con-
sists of women in whom menses failed to appear,
that is women who have primary amenorrhea. Be-
cause diagnostic evaluation ofthese three groups of
patients differs greatly this categorization makes a
more rational approach to diagnosis possible.
In Women Who Menstruate
While primary and secondary amenorrhea con-
stitute primafacie evidence offailure of coordinate
function of the hypothalamic-pituitary-ovarian-
genital axis, the converse is not true, since cyclic
bleeding may occur despite either failure to ovulate
or inadequate postovulatory corpus luteum func-
tion. For this reason, attention should be directed
toward presumptive evidence for ovulation and
corpus luteum function in women who have regular
cyclic menses. Appropriately timed collections of
one or two specimens of peripheral blood for mea-
surement of progesterone concentrations with or
without a simultaneous biopsy of the endometrium
constitute an adequate test of the normality of cor-
pus luteum function and thus of ovulation.
How can ovarian function be studied? Examining
blood levels of sex steroid hormones collected at
appropriate times in the cycle from women who are
menstruating or at anytime from women with
amenorrhea provide useful information. However,
such measurements are expensive and may not be
easily available to some physicians. As an alterna-
tive to measurement of blood hormone levels, it is
possible to examine the sex steroid hormone target
tissues in the genital tract for evidence of appropri-
ate stimulation.
Examination of a specimen of endocervical
mucus is a simple test for effects of estrogens and
progestogens. Quality and quantity ofendocervical
mucus depend on the sex steroid hormones. The
specimen can be obtained during vaginal examina-
tion and determinations made by gross inspection.
Examination ofendometrial morphology provides a
second simple test of the prevailing sex steroid
hormone milieu. Estrogens stimulate proliferation
and progestogens stimulate secretory transforma-
tion of this epithelium, and sequential cyclic
changes are characteristic.
Vaginal epithelial cells undergo characteristic
changes in response to estrogens and progestogens
secreted by the ovaries. These changes consist
principally in variations in the extent of cornifica-
tion and ofshedding ofthese cells. Ifthe patient has
neither vaginal nor endocervical infection, some
inferences can be drawn about the adequacy of
ovarian estrogen secretion by microscopic exami-
nation of approximately stained smears of vaginal
epithelial cells.
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sampling, an indirect indicator of ovulation is the
"'thermogenic shift" in the basal body temperature
curve (10). Graphs ofdaily basal body temperatures
obtained consecutively between two episodes of
vaginal bleeding show elevations ofmore than 0.5°C
at or around the time of ovulation. This "'shift"
from lower to higher temperatures reflects activity
of progestogens secreted by the ovulatory follicle
on the thermoregulatory apparatus in the hy-
pothalamus. While it constitutes a presumptive
indicator of ovulation, the thermogenic shift is not
an adequate measure of the adequacy of corpus
luteum function, since levels of progesterone re-
quired to produce this effect are less than those re-
quired to produce an appropriate secretory trans-
formation of the endometrium (10). Failure to ob-
serve the shift can be equated with failure ofovula-
tion. To determine adequacy of corpus luteum
function, specimens of blood obtained prior to and
following the thermogenic shift will indicate
whether serum progesterone levels have elevated
appropriately after the thermogenic shift.
Assuming that direct and indirect evidence of
ovulation and corpus luteum function have been
found to be normal, one should question whether
the genital tract secretions are conducive to proper
traverse of the sperm through the endocervical
canal, uterus and tubes to facilitate the encounter
with the ovum. A postcoital test will determine
whether this genital tract environment is "hostile"
to the sperm; shortly after intercourse, vaginal se-
cretions and endocervical secretions are examined
for numbers and motility of sperm. For reasons not
entirely clear presently, genital tract secretions of
some women are spermatocidal and infertility en-
sues.
If adequate numbers of sperm with normal motil-
ity are present in the vagina and in the endocervical
canal, one must raise the question as to whether
there is some obstruction preventing the transfer of
sperm into the fallopian tubes for the encounter
with the ovum. Patency of the fallopian tubes is
usually determined by the transcervical introduc-
tion of contrast media into the fallopian tubes fol-
lowed by appropriate x-rays to ascertain if the con-
trast medium spills into the abdominal cavity.
In Women with Secondary Amenorrhea
Clinical evaluation of individuals who are not
having cyclic menses, that is women with secon-
dary amenorrhea, is somewhat more complex. In
the overwhelming majority of instances, the abnor-
mality will be found to be in either the
hypothalamic-pituitary unit or the ovary. Measure-
ment ofthe concentrations of sex steroid hormones
and gonadotrophins in a single specimen of blood
collected in the basal state provides diagnostically
useful information in women in whom the cause of
secondary amenorrhea is primarily due to depletion
of oocytes from the ovary (11) or alternatively to
refractoriness ofthe follicular apparatus to gonado-
trophic stimulation (12, 13). In these women very
high serum levels of follicle stimulating hormone
and luteinizing hormone will be found comparable
to those from post-menopausal women, reflecting
low prevailing levels of E2 and/or P. Atrophic vagi-
nal epithelium and a significant reduction in the
quantity of endocervical mucus reflect inadequate
ovarian estrogen secretion. This evidence of low
estrogen coupled with sustained high levels of FSH
and LH in a basal specimen ofblood is diagnostic of
primary ovarian failure.
If ovarian failure has been ruled out, function of
the hypothalamic-pituitary unit should be
evaluated. For the purposes of this discussion ab-
normalities ofthe hypothalamic-pituitary unit which
eventuate in secondary amenorrhea and infertility
are classifiable into two major groups. The first
consists of hypothalamic-pituitary dysfunction and
the second consists of hypothalamic-pituitary fail-
ure. In persons with hypothalamic-pituitary dys-
function, hormone levels in the basal state are
within the range ofnormal in virtually 100% ofcases
(14, 15). Moreover, changes in serum hormone con-
centrations in response to perturbations are likewise
within normal limits. In general, administration of
estrogens and progestogens will suppress pituitary
gonadotrophin secretion and giving an antagonist to
the biological effects of estrogen will enhance
pituitary gonadotrophin secretion in these women
(1O, 16). In contrast to women with hypothalamic-
pituitary dysfunction, women with hypothalamic-
pituitary unit failure will have decreased concentra-
tions of gonadotrophins in specimens of peripheral
blood collected in the basal state and in the majority
of instances, will fail to respond appropriately fol-
lowing perturbations (14, 15). Hence, in both groups
measurement of hormone concentrations prior to
and following perturbations will increase the diag-
nostic value of these determinations.
The simplest of the perturbation tests consists in
the intramuscular or oral administration of a pro-
gestogen (14, 15). If the genital tract is patent, and
the ovary has secreted sufficient estrogen to stimu-
late proliferation of the endometrium, the adminis-
tration of a progestogen will be followed by vaginal
bleeding within one week. If the person does not
bleed, either the ovary has not secreted adequate
amounts of estrogen or the endometrium is refrac-
tory.
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ITo distinguish between these alternatives, it is
necessary to give an estrogen for a period of21 days
to stimulate endometrial proliferation followed by
the administration of the progestogen to induce
bleeding. Failure to bleed after sequential estrogen
and progestogen indicates refractory endometrium
which cannot respond to normal quantities of sex
steroid hormones (17).
If the individual fails to bleed in response to the
progestogen alone, but bleeds following the admin-
istration of estrogen and progestogen, the
pathophysiologic basis for the disorder may be in
the ovary or in the hypothalamic-pituitary unit. On
the other hand as noted above, if gonadotrophin
levels are elevated, an ovarian disorder is probable.
Iflevels ofFSH and LH in the basal state are low in
an individual who does not bleed following the ad-
ministration of the progestogen, failure of the
hypothalamic-pituitary unit is indicated, since nor-
mally the hypothalamic-pituitary unit should re-
spond to low prevailing levels of estrogen with se-
cretion of both FSH and LH (15). Once the diag-
nosis ofhypothalamic-pituitary unit failure has been
established, it is mandatory to determine the basis
for the failure. In many instances, this can be dis-
covered by radiographic examination of the sella
turcica and appropriate other tests of anterior
pituitary function.
In Women with Primary Amenorrhea
The diagnosis of infertility associated with pri-
mary amenorrhea usually requires more sophisti-
cated testing. In addition to the measurements of
hormones in the basal state and following perturba-
tions, it is essential to rule out congenital malfor-
mations of the genital tract, sex chromosomal ab-
normalities, and genetic defects in adrenal or ovar-
ian steroid hormone metabolizing enzyme systems
which predispose to primary amenorrhea (l).
Treatment of Infertility
The extent to which exposure to noxious chemi-
cal agents in the environment predispose to the de-
velopment of infertility in women remains to be de-
termined. However, use of drugs such as oral con-
traceptives (18) or tranquilizers (19) may result in
secondary amenorrhea. Stopping the drug will re-
sult in resumption of menses in some of these
women.
Once the etiologic basis of infertility has been
established, rational therapy is fortunately available
for some ofthese women. In women with secondary
amenorrhea who respond to a progestogen with
vaginal bleeding, the administration of an estrogen
antagonist is frequently sufficient to stimulate ovu-
lation, permitting conception and successful preg-
nancy (20). Doses of these substances need to be
titrated and administered under close surveillance
ofa physician in orderto avoid the hyperstimulation
syndrome which eventuates in multiple births. In
women in whom failure of the hypothalamic-
pituitary unit is the etiologic basis of infertility, ad-
ministration of gonadotrophins extracted from the
urine of postmenopausal women to stimulate fol-
licular growth, followed by administration of HCG
to stimulate ovulation will result in ovulation and
successful pregnancy in about 30% of cases (21).
Treatment of infertility in women with normal cy-
clic menses and adequate corpus luteum function is
more complicated but is likewise successful in
about 30% of cases.
In women with failure of the hypothalamic-
pituitary unit secondary to pituitary tumors secret-
ing prolactin, analogues of ergot which function as
dopamine antagonists have been used successfully
to reestablish cyclic ovulation followed by normal
pregnancies (22, 23). In some of these women re-
section of the pituitary tumor results in resumption
of normal functioning of the remaining normal
pituitary tissue, cyclic menses, ovulation, and fer-
tility (24).
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